Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK Goh
The funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding validation
Cambridge, UK, and Boston MA, USA, 13 January 2026: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced a USD $12 million financing extension, bringing the Company’s total Series C…
Oversubscribed £2.5M seed round led by Ahren Innovation Capital
Strategic collaboration with o2h to progress drug discovery programme
Cambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5M seed funding round. The Company also announced the signing of a strategic agreement with o2h discovery, a preclinical Contract Research Organisation with an integrated drug discovery platform. The partnership aims to launch a collaborative drug discovery programme…
Amsbio announces a new range of well characterized Adeno-Associated Virus (AAV) reference standards that enable researchers to significantly improve their AAV production processes.
Adeno-associated virus can be engineered to transport DNA of interest to target cells, without any viral genes - making them a highly desirable and safe tool for gene therapy. However, one of the greatest challenges in AAV production is that AAV preparations contain a considerable number of viral particles without gene payloads. Even after purification procedures, samples include empty capsids. In gene therapy…
Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations
Cambridge, UK, 12 January 2026 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Rebecca Simmons as Chief Operating Officer.
Rebecca will be responsible for scaling the Company’s global business operations and leading sustainable growth…
Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.
The initiative is designed to support breakthrough scientific discovery with the potential to advance human health and accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
All applications were reviewed by the AbbVie and Pioneer Group selection…
Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.
NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the
mitochondrial permeability…
Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asia
System strengthens Taiwan’s capabilities in protein drug discovery research
Cambridge, UK, and Boston MA, USA, 07 January 2026: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of…
Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies
Cambridge, UK, 07 January 2026 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Dr Steven Bishop as Chief Medical Officer (CMO). Previously Chief Data Officer, Steven’s new role reflects changes in company structure, in response to continued growth and commercial…
Welcome to 2026 with One Nucleus
By Tony Jones, CEO, One Nucleus
It feels great returning to work when it is striking that many people are feeling more optimistic about the Life Science sector investment outlook at present than at this time last year, or indeed for most of 2025. Deal flow in terms of private investment, M&A and follow-on financings appeared to be on the rise through late 2025.
It may be too early to feel confident the bear market is over, investment will flow and growth will return consistently, but the signs look very encouraging. Heading off to San Francisco at the…
LONDON, UK – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.Alethio Therapeutics is a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives. Backed by deep scientific and clinical expertise, the Company is…